TP53 and breast cancer: Treatment with myriocin increased NE invaginations in the BRCA1-deficient p53-deficient breast cancer cell line HCC-1937 and the effect of PARPi in compromising their survival (Fig. 5a–c and Supplementary Fig. 5a, b).